DDInter1897 DDInter734
Ulipristal is a selective progesterone receptor modulator used for the purposes of emergency contraception (Ella) and for the treatment of uterine fibroids (Fibristal). It is a derivative of 19-norprogesterone and has both antagonistic and partial agonist activity at the progesterone receptor. It also binds to glucocorticoid receptor, however compared to mifepristone (a progesterone receptor antagonist), ulipristal is more tolerable and has lower glucocorticoid activity and better binding affinity. Ulipristal is currently recommended as first line therapy for emergency contraception, due to improved efficacy and similar side effect profile as compared to the traditional use of levonorgestrel or the Yuzpe regimen. The exact mechanism of action for ulipristal is still currently debated, though there is evidence that it functions by inhibiting ovulation. A recent systematic review proclaimed that the majority of available evidence demonstrates
Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by _Clostridioides_ (formerly _Clostridium_) _difficile_ in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug. The antibacterial activity of fidaxomicin is distinct from macrolides and rifamycins, as the bactericidal activity is time-dependent, and not concentration-dependent. Fidaxomicin was the first macrocyclic lactone antibiotic with activity against _C. difficile_, and it displays a narrow spectrum of activity against gram-positive anaerobes. It mediates its potent bactericidal action on the bacteria by inhibiting the bacterial RNA synthase, thereby disrupting bacterial transcription. The minimum inhibitory concentration (MIC<sub>90</sub>) for fidaxomicin is four times less than that of [vancomycin], which was the primary drug of choice for _C. difficile_ infection before the approval of fidaxomicin. Unlike vancomycin, however, fidaxomicin has a negligible effect on normal colonic microflora. The FDA initially approved fidaxomicin in May 2011 for the treatment of _C. difficile_-associated diarrhea in adult patients over the age of 18. Later that year in December, the drug was also approved by the European Medicine Agency. In June 2012, fidaxomicin was also granted approval by Health Canada. The approved indication of fidaxomicin was expanded by the FDA in January 2020 to include pediatric patients over the age of 6 months in the treatment population.
Ulipristal {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clarithromycin
Clarithromycin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Fidaxomicin
Ulipristal {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Fidaxomicin
Ulipristal {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clarithromycin
Clarithromycin {u} (Compound) is included by {v} (Pharmacologic Class) Macrolides
Macrolides {u} (Pharmacologic Class) includes {v} (Compound) Fidaxomicin
Ulipristal {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) causes {v} (Side Effect) Flatulence
Flatulence {u} (Side Effect) is caused by {v} (Compound) Fidaxomicin
Ulipristal {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clarithromycin
Clarithromycin {u} (Compound) causes {v} (Side Effect) Flatulence
Flatulence {u} (Side Effect) is caused by {v} (Compound) Fidaxomicin
Ulipristal {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Afatinib
Afatinib {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Fidaxomicin
Ulipristal {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Afatinib
Afatinib {u} (Compound) causes {v} (Side Effect) Nervous system disorder
Nervous system disorder {u} (Side Effect) is caused by {v} (Compound) Fidaxomicin
Ulipristal may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Fidaxomicin (Compound)
Ulipristal may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Fidaxomicin (Compound)
Ulipristal may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin (Compound) is included by Macrolides (Pharmacologic Class) and Macrolides (Pharmacologic Class) includes Fidaxomicin (Compound)
Ulipristal may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Fidaxomicin (Compound)
Ulipristal may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Fidaxomicin (Compound)
Ulipristal may cause a moderate interaction that could exacerbate diseases when taken with Afatinib and Afatinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Fidaxomicin (Compound)
Ulipristal may cause a moderate interaction that could exacerbate diseases when taken with Afatinib and Afatinib (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Fidaxomicin (Compound)